Last reviewed · How we verify
Paliperidone ER
Paliperidone ER, marketed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., is an established treatment in the psychiatric market with a key composition patent expiring in 2028. A key strength of Paliperidone ER is its extended-release formulation, which enhances patient compliance and convenience. The primary risk to Paliperidone ER is the potential increase in generic competition following the 2028 patent expiry.
At a glance
| Generic name | Paliperidone ER |
|---|---|
| Also known as | Invega, 9-hydroxyrisperidone, Paliperidone, R076477 |
| Sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Paliperidone in Schizophrenia - Bangladesh Study (PHASE4)
- A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (PHASE3)
- An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia (PHASE3)
- Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients (PHASE4)
- Study of Paliperidone ER in Adolescents and Young Adults With Autism (PHASE3)
- Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia. (PHASE3)
- A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With Schizophrenia (PHASE4)
- IMPACT: A Study to Explore the Efficacy and Safety of Paliperidone ER in Patients With Acute Agitation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Paliperidone ER CI brief — competitive landscape report
- Paliperidone ER updates RSS · CI watch RSS
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. portfolio CI